Indications for PERFOROMIST:

Long-term maintenance treatment of COPD-associated bronchoconstriction.


20micrograms (1 vial) by nebulizer twice daily (AM & PM). Use standard jet nebulizer (eg, PARI-LC Plus [with face-mask or mouthpiece]) and air compressor (eg, Proneb Ultra compressor). Does not need to be diluted before nebulization. Do not mix with other drugs.


Not established.


In patients with asthma without use of a long-term asthma control medication.

Boxed Warning:

Asthma-related death.


LABA increase risk of asthma-related death. Do not initiate in acutely deteriorating COPD. Not for the treatment of asthma. Not for relief of acute symptoms. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Not for use with other long-acting β2-agonists. Do not exceed recommended dose. Cardiovascular disease (esp. hypertension, coronary insufficiency, arrhythmias). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Labor & delivery. Pregnancy. Nursing mothers.

Pharmacologic Class:

Long-acting beta-2 agonist (LABA).


Caution with MAOIs, tricyclics, others that prolong QTc interval (may cause ventricular arrhythmias). Antagonized by β-blockers. K+-depleting diuretics, xanthines, steroids may potentiate hypokalemia. Sympathetic effects potentiated by additional adrenergics (caution).

Adverse Reactions:

GI upset, nasopharyngitis, dry mouth, dizziness, insomnia; ECG changes or cardiovascular effects (eg, increased BP, tachycardia; consider discontinuing if occur); hypokalemia, hyperglycemia, metabolic acidosis; hypersensitivity reactions; rarely: paradoxical bronchospasm, increased risk of asthma-related death.

How Supplied:

Single-use vials (2mL)—60


2ml of 20mcg/2ml vial (Qty: 60)
Appx. price $971